Quick Facts

• Chronic Immune Thrombocytopenia (ITP): Used to support increased platelet counts in adults and children (one year and older) with persistent or chronic ITP who have not responded adequately to prior management options.
• Chronic Liver Disease (CLD) Thrombocytopenia: Administered to address low platelet counts in adult patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.

---

Avatrombopag is an oral therapeutic option indicated for managing low platelet levels, a condition known as thrombocytopenia, in specific patient populations. The medication is used in adult patients with chronic liver disease (CLD) who are preparing for a procedure.

This application is intended to contribute to an increase in the number of circulating platelets in advance of the medical or dental procedure. This approach may help reduce the need for platelet transfusions or other rescue procedures associated with bleeding events.

Avatrombopag also functions as a management approach for patients diagnosed with chronic or persistent immune thrombocytopenia (ITP). This includes adult patients and pediatric patients one year of age and older who have demonstrated an insufficient response to previous treatments. The objective of treatment in ITP is to support platelet production to maintain counts above a threshold that may mitigate the risk of spontaneous bleeding. It is not utilized to normalize platelet counts.

Regulatory References

1. NIH MedlinePlus guidance on Avatrombopag

Avatrombopag eligibility is defined by the official indications and specific population constraints documented in regulatory labeling.

Approved Populations

Indication	Eligible Age Group
Chronic Liver Disease (CLD) Thrombocytopenia	Adults scheduled to undergo a medical or dental procedure.
Chronic Immune Thrombocytopenia (ITP)	Adults and pediatric patients 1 year of age and older who have had an insufficient response to prior treatments.

Restrictions and Limitations

• Contraindications: Avatrombopag is contraindicated in patients with a known hypersensitivity to the active substance or any ingredient in the formulation.
• Platelet Count Normalization: The medicine must not be used in an attempt to normalize platelet counts (increase them beyond the upper threshold of therapy) in any patient population.
• Organ Impairment: Safety and efficacy are not established in patients with severe hepatic impairment (Child-Pugh class C, MELD score > 24) or severe renal impairment (CrCl < 30 mL/min).
• Pregnancy and Lactation: Use is not recommended during pregnancy due to potential fetal harm, and breastfeeding is not recommended during treatment and for two weeks after the last dose.

Avatrombopag is primarily metabolized by the liver enzymes CYP2C9 and CYP3A4/5. Medications that strongly increase or decrease the activity of these enzymes can significantly alter the level of Avatrombopag in the body.

Clinically Significant Interactions

Concomitant Medicine Category	Example Medicines	Interaction Effect	Required Action for Chronic ITP Use
Moderate or Strong Dual CYP2C9 and CYP3A4/5 Inhibitors	Fluconazole, Itraconazole, Verapamil	Increase Avatrombopag exposure (AUC)	Reduce the Avatrombopag starting dose
Moderate or Strong Dual CYP2C9 and CYP3A4/5 Inducers	Rifampin	Decrease Avatrombopag exposure (AUC)	Increase the Avatrombopag starting dose

For patients with chronic immune thrombocytopenia (ITP), a starting dose adjustment is necessary when beginning therapy concurrently with these types of inhibitors or inducers. If a strong inhibitor or inducer is added during ongoing Avatrombopag therapy, platelet counts must be monitored closely to guide dose modification.

For the short-term, 5-day regimen used in chronic liver disease (CLD), no dose adjustment for Avatrombopag is currently recommended with these interacting medicines, but the patient must be evaluated for unexpected changes in platelet count. Concomitant use with other ITP treatments requires platelet monitoring to keep counts within the target range. Avatrombopag, as a thrombopoietin receptor agonist, has been associated with thromboembolic complications, and caution is advised for patients with pre-existing risk factors, such as genetic prothrombotic conditions.

Targeting the Thrombopoietin Receptor (TPO-R) Agonism

Avatrombopag functions as a highly selective Thrombopoietin Receptor Agonist (TPO-RA). As a small molecule, it binds to the c-Mpl receptor (TPO-R), which is expressed primarily on the surface of bone marrow precursor cells. This binding interaction initiates an intracellular signaling cascade, specifically activating the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway, which serves as a key activator of cellular development.

Amplifying the Megakaryopoiesis Cascade

The activated signaling pathway drives the systemic process of megakaryopoiesis, which includes the proliferation and accelerated maturation of megakaryocyte progenitor cells within the bone marrow. This enhanced cellular output significantly increases the rate at which these cells fragment, resulting in the sustained release of a higher concentration of mature platelets into the peripheral bloodstream. The mechanism thus augments the cellular components required for blood coagulation, entirely dependent on the presence of viable progenitor cells.

Administration Scope

Avatrombopag is administered orally in the form of a 20 mg film-coated tablet or 10 mg oral granules. A mandatory condition for proper use is that all doses must be taken with food. The therapeutic objective for both indications is to support platelet production to mitigate the risk of bleeding, and the medicine should explicitly not be used to normalize platelet counts.

Dosing for Specific Conditions

Usage patterns are distinctly organized based on the patient's indication.

• Chronic Liver Disease (CLD) Thrombocytopenia: The medicine is administered as a short-term, fixed course of treatment for five consecutive days. The daily dose is determined by the patient's baseline platelet count, resulting in either a 40 mg or 60 mg regimen. This course must be initiated 10 to 13 days prior to a scheduled invasive procedure to ensure proper timing of platelet response.

• Chronic Immune Thrombocytopenia (ITP): Therapy is initiated and maintained as a long-term, chronic regimen. The standard adult starting dose is 20 mg once daily. Dosing is then adjusted (titrated) based on the patient's measured platelet count response, with adjustments made no more often than every two weeks, up to a maximum allowed dose of 40 mg once daily.

Special Administration Rules

For pediatric patients aged one to less than six years, the initial 10 mg dose must be administered using the oral granule formulation, which requires being mixed with a soft food or liquid and swallowed immediately. If a dose is missed, patients should take the dose as soon as it is remembered; however, they are instructed not to take two doses at one time to compensate for the missed dose.

Avatrombopag is a second-generation oral thrombopoietin receptor agonist (TPO-RA). It has been studied and authorized for use in specific populations with thrombocytopenia (low platelet count), primarily adults with chronic liver disease (CLD) and adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatments.

Efficacy in Chronic Liver Disease

Clinical trials (ADAPT-1 and ADAPT-2) evaluated avatrombopag in adults with chronic liver disease who were scheduled to undergo a procedure. The primary measure of effectiveness was the proportion of participants who did not require a platelet transfusion or rescue procedure for bleeding within seven days following the elective procedure.

Research found that a greater proportion of participants treated with avatrombopag achieved this primary endpoint compared to the placebo groups in both trials, demonstrating an increase in platelet count sufficient to reduce the need for transfusion.

Efficacy in Chronic Immune Thrombocytopenia

Studies in adults with chronic ITP found that avatrombopag was associated with an increased platelet response. In the pivotal Phase 3 study, participants receiving the active compound had a significantly greater median cumulative number of weeks with a platelet count of 50 imes 10^9/L compared to those receiving placebo. This increase in platelet count was achieved in the absence of rescue therapy.

Safety Profile and Adverse Events

Commonly reported adverse reactions across clinical trials included headache, fatigue, pyrexia (fever), abdominal pain, and nausea. Avatrombopag is designed to stimulate platelet production without increasing platelet activation, and clinical data has noted minimal hepatic toxicity.

Common questions about Avatrombopag (FAQ)

---

Q: Is Avatrombopag a chemotherapy drug?

Avatrombopag is classified by regulatory documents as a Thrombopoietin Receptor Agonist (TPO-RA). This type of medicine is not a chemotherapy agent; it works by stimulating the bone marrow to produce platelets, which helps to increase the platelet count.

---

Q: Does Avatrombopag work immediately, or does it take time?

Avatrombopag does not work immediately. Official pharmacological data indicates that the increase in platelet count is typically observed within 3 to 5 days of starting the 5-day course. The peak effect has typically been observed around 10 to 13 days.

---

Q: How quickly can someone expect Avatrombopag to start having an effect?

According to official product information, platelet counts have been observed to begin increasing within 3 to 5 days after treatment initiation. This effect allows the body time to produce and release new platelets into the bloodstream.

---

Q: Can Avatrombopag be taken with common pain relievers like Tylenol (acetaminophen)?

Regulatory labeling focuses on drug-drug interactions involving specific liver enzymes (CYP2C9 and CYP3A4/5) that process Avatrombopag. Acetaminophen is not listed as a strong dual inhibitor or inducer of these specific enzymes that would require a mandatory dose adjustment when starting treatment.

---

Q: What happens if I miss a dose of Avatrombopag?

Official administration rules state that if a dose is missed, the patient should take that dose as soon as they remember. Official administration rules indicate that patients should not take two doses at one time to compensate for a missed dose.

---

Q: Is it safe to drink alcohol while taking Avatrombopag?

A direct interaction with alcohol is not specifically listed in the official prescribing information. However, patients are advised in the labeling to discuss the use of alcohol with a healthcare professional, as interactions may occur with certain medicines.

---

Q: Is Avatrombopag safe for patients with kidney problems?

The official safety profile notes that safety and effectiveness have not been established for patients who have severe renal impairment (a serious form of kidney problem). Regulatory data indicates the medicine is only minimally removed from the body by the kidneys.

---

Q: Can Avatrombopag be used by children?

Yes, regulatory documents indicate that Avatrombopag is approved for use in pediatric patients 1 year of age and older. This use is specifically for the treatment of chronic immune thrombocytopenia (ITP) in this age group.

---

Q: Does Avatrombopag affect fertility or pregnancy planning?

Based on findings from animal studies, Avatrombopag may cause fetal harm if taken during pregnancy. Due to this potential risk, official labeling indicates that effective contraception should be used by females of childbearing potential during treatment.

--UN

Q: Does Avatrombopag require any specific blood tests before starting treatment?

Yes, the official prescribing information states that patients are required to have their platelet count measured before starting treatment. Ongoing monitoring of platelet counts is also necessary during and after treatment.

---

Q: What is the typical length of time people stay on Avatrombopag?

The duration of use is different depending on the condition being treated. For chronic liver disease (CLD), it is a short-term, fixed course for only five consecutive days. For chronic immune thrombocytopenia (ITP), it is started and maintained as a long-term, chronic regimen.

---

Q: Does Avatrombopag interact with common stomach acid reducers?

The drug's primary metabolism involves specific CYP liver enzymes. Official documents note that Avatrombopag absorption is not dependent on stomach pH, meaning no specific interaction with common stomach acid reducers is noted.

---

Q: Is Avatrombopag considered a blood thinner?

Avatrombopag is classified as a Thrombopoietin Receptor Agonist, which works to increase platelet production, rather than thinning the blood. However, official safety notes indicate that TPO receptor agonists are associated with a regulatory risk of thrombotic or thromboembolic complications (blood clots).

---

Q: What if I vomit shortly after taking a dose of Avatrombopag?

Official patient instructions indicate that if vomiting occurs shortly after taking a dose, patients should contact a healthcare provider for further guidance. This is to ensure appropriate advice can be given based on the timing and situation.

---

Q: Can Avatrombopag be stopped suddenly, or does the dose need to be reduced slowly?

Official documentation notes that platelet counts are expected to decrease after stopping the medication, generally returning toward baseline levels within one to two weeks. For ITP, the dosage is often adjusted (titrated) based on measured platelet counts.

---

Q: How does Avatrombopag compare in terms of convenience (e.g., pill vs injection) to similar treatments?

Regulatory documents describe Avatrombopag as an oral tablet and a non-peptide small molecule. This feature is noted as a key structural and administration distinction from some other treatments in the same therapeutic class, which may require injection.

---

Q: Is it possible to take too much Avatrombopag?

Official product information on overdose indicates that taking too much may lead to an excessive increase in platelet count. This excessive increase could potentially raise the risk of thrombotic or thromboembolic complications.

---

Q: Are there any known interactions between Avatrombopag and herbal products?

Avatrombopag is metabolized by the liver enzymes CYP2C9 and CYP3A4/5. Herbal products known to strongly affect the activity of these specific enzymes could alter the level of the drug in the body, although specific herbal products are not named in the labeling.

---

Q: What is the half-life of Avatrombopag?

Official pharmacological data states that the mean plasma elimination half-life of avatrombopag is approximately 19 hours. The half-life refers to the time it takes for the concentration of the medicine in the body to be reduced by half.

Official Storage and Disposal Requirements

This information is based on authoritative government regulatory labeling for Avatrombopag (Doptelet).

Requirement Area	Official Instruction
Storage Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Packaging	Keep the tablets or sprinkle capsules in the original container until the time of use.
Child Safety	Keep Avatrombopag and all medicines out of the reach of children.
Disposal	Dispose of any unused or expired product according to local, state, and federal laws.
Environmental Rule	The product must not be disposed of by flushing down the toilet or pouring down a drain. Consult a pharmacist or local waste disposal service for guidance on proper disposal.